Compare TKC & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKC | BLCO |
|---|---|---|
| Founded | 1993 | 1853 |
| Country | Turkey | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Ophthalmic Goods |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 6.0B |
| IPO Year | 2000 | 2022 |
| Metric | TKC | BLCO |
|---|---|---|
| Price | $5.91 | $16.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $17.31 |
| AVG Volume (30 Days) | ★ 903.5K | 351.6K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | $4,451,876,110.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $42.76 | $8.08 |
| Revenue Next Year | $29.15 | $5.77 |
| P/E Ratio | $22.64 | ★ N/A |
| Revenue Growth | N/A | ★ 6.23 |
| 52 Week Low | $5.35 | $10.45 |
| 52 Week High | $7.63 | $18.99 |
| Indicator | TKC | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 58.82 |
| Support Level | $5.86 | $16.83 |
| Resistance Level | $6.15 | $17.33 |
| Average True Range (ATR) | 0.07 | 0.45 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 52.53 | 52.69 |
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.